PLUR

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

Wall Street analysts forecast PLUR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLUR is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Pluri Inc revenue for the last quarter amounts to 316.00K USD, decreased -3.07 % YoY.

Pluri Inc. EPS for the last quarter amounts to -0.65 USD, decreased -39.81 % YoY.

Pluri Inc (PLUR) has 106 emplpoyees as of December 15 2025.

Today PLUR has the market capitalization of 28.50M USD.